Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.

Autor:	García-Layana A; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Chi GC; Genentech, Inc., South San Francisco, California, USA., Kodjikian L; Department of Ophthalmology, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.; UMR-CNRS 5510 Matéis, Insa, University of Lyon, Lyon, France., Parravano M; IRCCS-Fondazione Bietti, Rome, Italy., Chow D; Toronto Retina Institute, Toronto, Ontario, Canada., Jackson TL; Faculty of Life Science and Medicine, King's College London, London, UK., Danzig C; Rand Eye Institute, Deerfield Beach, Florida, USA., Paris LP; Genentech, Inc., South San Francisco, California, USA., Mirt M; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Henry-Szatkowski M; Patient Centred Outcomes, ICON plc, London, UK., Lewis HB; Patient Centred Outcomes, ICON plc, London, UK., Gentile B; Genentech, Inc., South San Francisco, California, USA.
Jazyk:	angličtina
Zdroj:	Ophthalmic research [Ophthalmic Res] 2025; Vol. 68 (1), pp. 13-22. Date of Electronic Publication: 2024 Nov 21.
DOI:	10.1159/000541349
Abstrakt:	Introduction: New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options. Methods: This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data. Results: Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring "injection" over "implant surgery and refills" and better visual outcomes over "stabilization," which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for "mild-moderate, frequent" over "severe, rare" side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD). Conclusion: Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options. (© 2024 The Author(s). Published by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu